Discovery Program. (a) From the Effective Date, the objective of the Parties during the Discovery Program is for Regeneron to discover, identify and/or validate Targets from which Regeneron shall select Targets for the Rolling Target List, generate MTCs (and, if agreed to by the JRC, other Antibodies) against Program Targets (including Program Targets that are Sanofi Targets) from which to select Lead Candidates, and develop such Lead Candidates through IND Preparation to offer to Sanofi for joint development and commercialization under the terms set forth herein and in the License and Collaboration Agreement. During the first ten (10) Contract Years, Regeneron will use Commercially Reasonable Efforts to discover, identify and validate Targets as part of the Discovery Program. The Parties will select Targets for the Rolling Target List pursuant to Section 2.4. *******************************************. Regeneron will use Commercially Reasonable Efforts to generate MTCs (and if agreed by the JRC, other Antibodies) against Program Targets and manufacture preclinical and clinical supplies of the Lead Candidates and Product Candidates for the Discovery Program and Phase 1 Clinical Trials. The JRC will evaluate and prioritize Program Targets. Subject to the JRC’s prioritization of Program Targets, Sanofi’s Target selection and exclusion rights under Section 2.4, and the other terms of this Agreement, Regeneron will have sole responsibility for the design and conduct of all activities under the Discovery Program, including, without limitation, decisions relating to initiation and termination of programs and activities, manufacturing activities, and staffing and resource allocation between different programs and activities in the Discovery Program. The JRC will also prioritize the Antibodies, including MTCs, to be further pursued as Lead Candidates, and Regeneron will commence IND Preparation activities only for those Antibodies, including MTCs, that meet the applicable criteria set forth in Schedule 4. Sanofi shall be responsible for completing relevant portions of Schedule 4 for all Sanofi Targets at the time that such Target is selected for the Rolling Target List to the extent such information is not available at Regeneron. Sanofi, through the JRC, will provide consultation and advice to support Regeneron’s efforts. Neither Regeneron nor Regeneron’s representative on the JRC shall have the right to discriminate against Sanofi Targets without the agreement of Sanofi’s represen...
Discovery Program. During the Option Term, Agios shall be responsible for conducting discovery research activities with the principal goals of (i) identifying and validating Collaboration Targets in accordance with the Validation Criteria, (ii) identifying and discovering Collaboration Compounds that either activate or inhibit through direct binding to a Collaboration Target, (iii) nominating Development Candidates, and (iv) characterizing, optimizing and supporting the pre-clinical Development of Development Candidates, including IND-Enabling Studies; provided that, if Celgene and Agios both consent, Celgene may also be assigned responsibility for some of the foregoing discovery research activities at Agios’ sole expense.
Discovery Program. Future Fellowships Grant Details C1 Purpose of the Grant
Discovery Program. During the Option Term, Array shall be responsible for conducting a discovery research program (the “Discovery Program”).
Discovery Program. SELECTED QTS
Discovery Program. During the Option Term, Array and, if directed by the JRC, JDC or JMC and expressly agreed by Celgene in writing, Celgene shall be responsible for conducting a discovery research program with the principal goals of: (i) identifying and discovering Compounds that directly modulate each of the Targets; (ii) characterizing, optimizing and supporting the pre-clinical development of such Compounds; (iii) conducting a Phase I clinical trial and, where applicable under Section 3.7.3 below, a Phase II clinical trial with respect to Compounds that have been designated as Development Compounds pursuant to Section 3.5 below; and (iv) if required pursuant to Section 3.7.4 below, conducting continued preclinical development and potentially a Phase I clinical trial with respect to certain Development Back-Up Compounds (“Discovery Program”). During the Option Term, Array shall, on a Target-by-Target basis, use Diligent Efforts to conduct the Discovery Program with respect to such Target.
Discovery Program. Section 2.1 TARGET DISCOVERY PROGRAM OVERVIEW. The primary objective of the Target Discovery Program is to identify and qualify a minimum of 225 QTs during the Discovery Program Term. The principal focus of the Target Discovery Program shall be the identification and qualification of CFA QTs, based upon a Target by Class Drug Discovery Approach. In addition to the foregoing, the Discovery Program may include work directed at [**] or work utilizing approaches for the discovery of targets for Small Molecules other than a Target by Class Drug Discovery Approach, but only if mutually agreed upon by the Parties and reflected in the Research Plan. Millennium shall use commercially reasonable efforts to generate and enter into the Discovery Pool a minimum of 225 QTs over the course of the Discovery Program Term.
Discovery Program. Each Party agrees to use its commercial best efforts to perform the research discovery program (the Discovery Program) set forth in the scope of work in Attachment I annexed hereto (the Scope of Work) within the time frame designated herein. IAVI will also conduct and fund additional activities supportive of, and related to, the Discovery Program, including collection of donor samples, assay development and assay testing at Monogram Biosciences, activities related to the Program Team (as defined below), and the characterization of the Final MAbs (as defined in the Scope of Work).
Discovery Program. 2.4.1 The Discovery Program commenced on [*], and Penn shall continue to perform the Discovery Program in accordance with this Agreement for the duration of the Discovery Term. Upon mutual agreement by the Parties prior to the expiration of the Discovery Term, the Discovery Term may be extended for an additional [*].
Discovery Program. 2.1 Discovery Program 11 2.2 Term of the Discovery Program 12 2.3 Discovery Plans 12 2.4 Target List 13 2.5 Commercially Reasonable Efforts; Compliance with Laws 14 2.6 Exchange of Information 15 2.7 Further Assurances and Transaction Approvals 15 2.8 Exclusive Discovery Program 15 2.9 Tail Period 18 2.10 Research Licenses; Licenses Generally 18 2.11 Immunoconjugates 18 2.12 Sanofi Target Licenses 18 2.13 Non-Exclusive License to Sanofi 18 2.14 Invention Assignment 19 2.15 Supply of VelociGene® Mice 19 2.16 Option for VelocImmune License 19 2.17 Option for Additional Technologies 19 2.18 Third Party Platform Licenses 19 ARTICLE 3 JOINT RESEARCH COMMITTEE 3.1 The Joint Research Committee 19 3.2 Alliance Management 21 3.3 Resolution of Governance Matters 21 3.4 Obligations of the Parties and their Affiliates 22 ARTICLE 4
